Search results
Dr. Jeff Hersh addresses cause, effects and complications of Graft vs Host Disease
Gannett via AOL· 5 days agoGraft vs Host Disease occurs when white blood cells produced by donated stem cells identify the...
The Ins And Outs Of Modern Barrier Systems For Sterile Manufacturing
BioresearchOnline· 3 days agoBarrier systems include restricted access barrier systems (RABS) and isolators. To prevent direct...
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D...
Morningstar· 2 days agoFN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than doubled. In 2000, it was estimated by the National ...
Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as...
WKRN Nashville· 14 hours agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology ...
Scaling Rapid Cycling Membrane Chromatography From Bench To Commercial Manufacturing
BioresearchOnline· 4 days agoThe goal of this study was to demonstrate the successful scale-up of a rapid cycling chromatography (RCC) process from a generic bench chromatography system to the Resolute® RCC MU and Resolute ...
Stocks making the biggest moves midday: Five Below, Salesforce, Lululemon, Instacart and more
CNBC· 7 days agoCheck out the companies making headlines in midday trading: Five Below — Shares of Five Below sank...
Inebilizumab 'MITIGATES' Flare Risk in IgG4-Related Disease
Medscape· 6 days agoInebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 35,000 Shares
ETF DAILY NEWS· 1 day agoY-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 35,000 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 3 days agoTOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “
Short bouts of exercise may boost efficacy of some types of cancer treatment
MedicalNewsToday via AOL· 7 days agoRecent research suggests that short bouts of moderate to intense exercise could boost the efficacy...